Clinical Trials Search Results

study evaluating adoptive cell therapy with TIL LN-144 (Lifileucel)/LN-145 in combo w/ checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1, single agent therapy

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases).

2 phases. Participants will receive modakafusp alfa for up to 1 year (Phase 1b) or modakafusp alfa given together with pembrolizumab for up to 2 years (Phase 2).